Ukr.Biochem.J. 2022; Volume 94, Issue 6, Nov-Dec, pp. 48-56

doi: https://doi.org/10.15407/ubj94.06.048

Serum visfatin, resistin levels and inflammation markers in psoriasis patients

13.02.2023   Uncategorized   No comments

A. Majid*, M. Fouad

Department of Chemistry, College of Science, University of Thi-Qar, Thi-Qar, 64001, Iraq;
*e-mail: aliaa.s_mschem@sci.utq.edu.iq

Received: 08 October 2022; Revised: 02 December 2022;
Accepted: 17 February 2023; Available on-line: 27 February 2023

Psoriasis is a common chronic inflammatory skin condition that varies in severity. Psoriasis is associated with complex disorders, which incorporate metabolic syndrome, obesity and impaired glucose tolerance. Adipose tissue secretes several hormones and cytokines, in particular visfatin and resistin that could be involved in the development of psoriasis by acting as pro-inflammatory or immunoregulatory factors. The aim of this work was to evaluate the serum level of visfatin and resistin as well as of high-sensitivity C-reactive protein (hs-CRP) and erythrocyte sedimentation rate (ESR) in psoriatic patients. The study included 43 healthy individuals and 45 patients divided into three groups with mild, moderate and severe clinical degrees of disease assessed by the Psoriasis Area Severity Index (PASI). The results showed a significant increase in the concentration of serum visfatin, resistin, ESR and hs-CRP in patient groups in comparison with a control group. The highest increase in indicators was observed in the group of patients with severe disease compared with the mild and moderate patients groups. The significance of studied indicators as biomarkers of psoriasis disease severity is analyzed.

Keywords: , , , ,

References:

  1. Ritchlin C, Fitzgerald O. Psoriatic and Reactive Arthritis: A Companion to Rheumatology. (1st ed.). Maryland Heights, Miss: Mosby, 2007. 256 p.
  2. Gerdes S, Mrowietz U, Boehncke WH. Comorbidity in psoriasis. Hautarzt. 2016;67(6):438-444. PubMed, CrossRef
  3. Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol. 2008;159(Suppl 2):2-9. PubMed, CrossRef
  4. Malkic Salihbegovic E, Hadzigrahic N, Cickusic AJ. Psoriasis and metabolic syndrome. Med Arch. 2015;69(2):85-87. PubMed, PubMedCentral, CrossRef
  5. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000-1006. PubMed, PubMedCentral, CrossRef
  6. Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol. 2007;157(4):649-655. PubMed, CrossRef
  7. Gerkowicz A, Pietrzak A, Szepietowski JC, Radej S, Chodorowska G. Biochemical markers of psoriasis as a metabolic disease. Folia Histochem Cytobiol. 2012;50(2):155-170. PubMed, CrossRef
  8. Nijsten T, Wakkee M. Complexity of the association between psoriasis and comorbidities. J Invest Dermatol. 2009;129(7):1601-1603. PubMed, CrossRef
  9. Naif AAH. Metabolic syndrome in Iraqi patients with psoriasis: A comparative study. J Thi-Qar Sci. 2015;5(2):37-39. CrossRef
  10. Furue M, Furue K, Tsuji G, Nakahara T. Interleukin-17A and Keratinocytes in Psoriasis. Int J Mol Sci. 2020;21(4):1275. PubMed, PubMedCentral, CrossRef
  11. Woźniak A, Drewa G, Krzyzyńska-Maliniowska E, Czajkowski R, Protas-Drozd F, Mila-Kierzenkowska C, Rozwodowska M, Sopońska M, Czarnecka-Zaba E. Oxidant-antioxidant balance in patients with psoriasis. Med Sci Monit. 2007;13(1):CR30-CR33. PubMed
  12. Luty-Frackiewicz A, Markiewicz-Gorka I,Januszewska L. Influence of smoking and alcohol consumption on total antioxidant status in patients with psoriasis. Adv Clin Exp Med. 2006;15(3):463-469.‏
  13. Matsushita T, Hasegawa M, Shirasaki F, Fujimoto M, Yamazaki H, Sato S, Takehara K. A case of acute cutaneous graft-versus-host disease mimicking psoriasis vulgaris. Dermatology. 2008;216(1):64-67. PubMed, CrossRef
  14. Choi KM, Kim JH, Cho GJ, Baik SH, Park HS, Kim SM. Effect of exercise training on plasma visfatin and eotaxin levels. Eur J Endocrinol. 2007;157(4):437-442. PubMed, CrossRef
  15. Al-Suhaimi EA, Shehzad A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res. 2013;18(1):12. PubMed, PubMedCentral, CrossRef
  16. Hognogi LDM, Simiti LV. The cardiovascular impact of visfatin – an inflammation predictor biomarker in metabolic syndrome. Clujul Med. 2016;89(3):322-326. PubMed, PubMedCentral, CrossRef
  17. Romacho T, Sánchez-Ferrer CF, Peiró C. Visfatin/Nampt: an adipokine with cardiovascular impact. Mediators Inflamm. 2013;2013:946427. PubMed, PubMedCentral, CrossRef
  18. Okan G, Baki AM, Yorulmaz E, Doğru‐Abbasoğlu S, Vural P. Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity. J Clin Lab Anal. 2016;30(4):284-289. PubMed, PubMedCentral, CrossRef
  19. Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada N, Okamoto Y, Nagaretani H, Nishizawa H, Kishidav, Komuro R, Ouchi N, Kihara S, Nagai R, Funahashi T, Matsuzawa Y. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem. 2002;277(40):37487-37491. PubMed, CrossRef
  20. Steppan CM, Bailey, ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307-312. PubMed, CrossRef
  21. Schwartz DR, Lazar MA. Human resistin: found in translation from mouse to man. Trends Endocrinol Metab. 2011;22(7):259-265. PubMed, PubMedCentral, CrossRef
  22. Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, Enders GH, Silberg DG, Wen X, Wu GD, Lazar MA. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA. 2001;98(2):502-506. PubMed, PubMedCentral, CrossRef
  23. Zbaar SA.Resistin serum levels in psoriasis patients and association with disease severity in Iraqi population. Tikrit Med J. 2015;20(2):52-59.‏
  24. Nazal FY. A Comparative Study of High Level laser and Low Level laser and Temperature on the Erythrocytes Sedimentation Rate Values in Healthy People: In Vitro Study. Thi-Qar Med J. 2017;14(2):49-59. CrossRef
  25. Mack DR, Langton C, Markowitz J, LeLeiko N, Griffiths A, Bousvaros A, Evans J, Kugathasan S, Otley A, Pfefferkorn M, Rosh J, Mezoff A, Moyer S, Oliva-Hemker M, Rothbaum R, Wyllie R, delRosario JF, Keljo D, Lerer T, Hyams J. Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics. 2007;119(6):1113-1119. PubMed, CrossRef
  26. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol. 2004;29(8):439-493. PubMed
  27. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem. 2001;47(3):403-411. PubMed
  28. Niknezhad N, Haghighatkhah HR, Zargari O, Ghalamkarpour F, Younespour S, Niknejad N, Alikhan A, Abdollahimajd F. High-sensitivity C-reactive protein as a biomarker in detecting subclinical atherosclerosis in psoriasis. Dermatol Ther. 2020;33(4):e13628. PubMed, CrossRef
  29. Vadakayil AR, Dandekeri S, Kambil SM, Ali NM. Role of C-reactive protein as a marker of disease severity and cardiovascular risk in patients with psoriasis. Indian Dermatol Online J. 2015;6(5):322-325. PubMed, PubMedCentral, CrossRef
  30. Mousa HM, Hassan AG. Interleukin-17 serum levels as a vital indicator of psoriatic Iraqi patients in Thi-Qar Province. EurAsian J BioSci. 2020;14(1):1101-1104.‏
  31. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385. PubMed, CrossRef
  32. Dowlatshahi EA. Psoriasis & Comorbidities: Unraveling the Maze. ‏2014.
  33. Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med. 2007;13(3):242-244. PubMed, CrossRef
  34. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866-873. PubMed, CrossRef
  35. Stofkova A. Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity. Endocr Regul. 2010;44(1):25-36. PubMed, CrossRef
  36. Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A, Damås JK, Tunheim SH, Ueland T, Smith C, Bendz B, Tonstad S, Gullestad L, Frøland SS, Krohg-Sørensen K, Russell D, Aukrust P, Halvorsen B. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation. 2007;115(8):972-980. PubMed,CrossRef
  37. Axelsson J, Witasp A, Carrero JJ, Qureshi AR, Suliman ME, Heimbürger O, Bárány P, Lindholm B, Alvestrand A, Schalling M, Nordfors L, Stenvinkel P. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis. 2007;49(2):237-244. PubMed, CrossRef
  38. Pang SS, Le YY. Role of resistin in inflammation and inflammation-related diseases. Cell Mol Immunol. 2006;3(1):29-34. PubMed
  39. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005;174(9):5789-5795. PubMed, CrossRef
  40. Filková M, Haluzík M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol. 2009;133(2):157-170. PubMed, CrossRef
  41. SilswalN, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun. 2005;334(4):1092-1101. PubMed, CrossRef
  42. Wolk K, Sabat R. Adipokines in psoriasis: An important link between skin inflammation and metabolic alterations. Rev Endocr Metab Disord. 2016;17(3):305-317. PubMed, CrossRef
  43. Shen J, Shang Q, Li EK, Leung YY, Kun EW, Kwok LW, Li M, Li TK, Zhu TY, Yu CM, Tam LS. Cumulative inflammatory burden is independently associated with increased arterial stiffness in patients with psoriatic arthritis: a prospective study. Arthritis Res Ther. 2015;17(1):75. PubMed, PubMedCentral, CrossRef
  44. Kyriakou A, Patsats A, Sotiriadis D, Goulis DG. Serum Leptin, Resistin, and Adiponectin Concentrations in Psoriasis: A Meta-Analysis of Observational Studies. Dermatology. 2017;233(5):378-389. PubMed, CrossRef
  45. Lamas J, Santos Y, Bruno DW, Toranzo AE, Anadon R. Non‐specific cellular responses of rainbow trout to Vibrio anguillarum and its extracellular products (ECPs). J Fish Biol. 1994;45(5):839-854. CrossRef
  46. Helliwell PS, Marchesoni A, Peters M, Platt R, Wright V. Cytidine deaminase activity, C reactive protein, histidine, and erythrocyte sedimentation rate as measures of disease activity in psoriatic arthritis. Ann Rheum Dis. 1991;50(6):362-365. PubMed, PubMedCentral, CrossRef
  47. Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, Dann F. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol. 2008;159(2):322-330. PubMed, CrossRef
  48. Gerdes S, Osadtschy S, Rostami-Yazdi M, Buhles N, Weichenthal M, Mrowietz U. Leptin, adiponectin, visfatin and retinol-binding protein-4 – mediators of comorbidities in patients with psoriasis? Exp Dermatol. 2012;21(1):43-47. PubMed, CrossRef
  49. Park S, Lakatta EG. Role of inflammation in the pathogenesis of arterial stiffness. Yonsei Med J. 2012;53(2):258-261. PubMed, PubMed, CrossRef
  50. Jain K, Krishna A, Rathore BS. Assessing disease severity by hsCRP as a biochemical marker for psoriasis. Int J Res Dermatology. 2017;3(4):501-505. CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.